10 Biotech Stories You Might've Missed This Week
As expected, it was a busy week for biotechs during the J.P. Morgan Healthcare Conference. Here's a recap of some of the news from the past week.
2. Celgene And Pharmacyclics' Positive Guidance
Celgene Corporation (NASDAQ: CELG) and Pharmacyclics, Inc. (NASDAQ: PCYC) announced positive revenue guidance. Pharmacyclics released preliminary revenue results for 2014 of $492 million. $185 million came from the fourth quarter, which was a 31 percent increase from the previous quarter. These numbers beat investor expectations.
3. Sarepta's Six Minute Walk Test
4. Roche-Foundation Medicine
Roche Holding Ltd. (ADR) (OTCMKTS:RHHBY) announced it is acquiring a majority stake in genomics company Foundation Medicine Inc (NASDAQ: FMI) at $50 per share.
5. Bristol Myers Squibb & Opdivo
Bristol-Myers Squibb Co (NYSE: BMY) announced it was stopping its Phase 3 study of Opdivo early for efficacy. The drug worked so well that the trial hit primary endpoints before expected. The company also announced collaborations with Seattle Genetics, Inc. (NASDAQ: SGEN) and Eli Lilly and Co (NYSE: LLY) to evaluate Opdivo in combination with other drugs.
6. CAR-T News
In CAR-T news, Intrexon Corp (NYSE: XON) and ZIOPHARM Oncology Inc (NASDAQ: ZIOP) announced a joint licensing agreement with MD Anderson to develop chimeric antigen receptor T cell (CAR-T) therapies. The two companies are paying MD Anderson $50 million each, payable in shares of their stock.
7. A Trio Of Presentations
8. Agenus' Partnership With Incyte
Agenus Inc (NASDAQ: AGEN) reached a partnership agreement with Incyte Corporation (NASDAQ: INCY) to develop immuno-therapies. Agenus received $25 million upfront, a $35 million investment at $4.51 per share, and $350 million in milestone payments.
9. SEC Investigation At Aegerion
On January 13, investors discovered that the SEC is investigating Aegerion Pharmaceuticals, Inc (NASDAQ: AEGR) for Juxtapid sale activities.
10. MannKind Loses Mann
Image credit: Sergei Goryev, Flickr
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.